Seven O’Melveny Lawyers Named LMG Life Sciences 2019 “Stars”

FOR IMMEDIATE RELEASE

NEW YORK—September 25, 2019—Seven O’Melveny lawyers have been named LMG Life Sciences 2019 “Stars,” recognized by the publication as preeminent life sciences practitioners in the US. LMG Life Sciences is a leading guide to top North American law firms and lawyers specializing in the life sciences industry.

O’Melveny’s Life Sciences Stars include:

• Steve Brody (DC), Non-IP Litigation & Enforcement
• Maggie Carter (LA), Non-IP Litigation & Enforcement
• Richard Goetz (LA), Non-IP Litigation & Enforcement
• John Kappos (NB), Intellectual Property
• Lisa Pensabene (NY), Intellectual Property
• Daniel Petrocelli (CC), Non-IP Litigation & Enforcement
• Scott Voelz (LA), Non-IP Litigation & Enforcement

In addition, O’Melveny was ranked as a recommended firm in the category of Hatch-Waxman Patent Litigation (Branded). In its analysis of the firm’s Intellectual Property practice, LMG cited peer reviews hailing O’Melveny as a “terrific firm” and “very strategic and talented team.”

LMG noted that Lisa Pensabene, chair of O’Melveny’s Life Sciences Litigation Practice, brings significant expertise in pharmaceutical patent disputes, work that earned her a place on the shortlist for LMG’s Branded Hatch-Waxman Litigator of Year award. The guide also observed that partner John Kappos is another “noteworthy litigator at the firm” with “two decades of experience in law.”

In its analysis of the firm’s non-IP litigation and enforcement work, LMG recognized “celebrity courtroom ace” Daniel Petrocelli, chair of O’Melveny’s Trial Practice Committee, for his work in securing a complete defense verdict for Janssen Pharmaceuticals and Johnson & Johnson in the first bellwether trial in a California Coordinated Proceeding involving more than 10,000 claims over the antipsychotic medication Risperdal.

LMG also credited partner Rich Goetz, co-chair of O’Melveny’s Litigation Department, for his defense of Amylin, a subsidiary of AstraZeneca, against claims brought by hundreds of plaintiffs in personal injury cases involving Byetta, an injectable medication for type-2 diabetes, in a California Coordinated Proceeding and a federal multidistrict litigation.

O’Melveny’s life sciences team understands the challenges faced by pharmaceutical, medical device, and diagnostics companies, both large and small. Our ranks include former scientists with advanced degrees in chemistry and biology, former life-science industry regulators with the “insider perspective” to deftly steer clients through related governmental inquiries, and boardroom-level counselors with strong ties to the entrepreneurs, scientists, and venture capital firms that drive innovation in the life sciences sector.

About O’Melveny

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at omm.com.

Contact: